EVTEvotec SE
4.700EUR+3.07%Mkt Cap: 820.13M EURP/E: Last update: 2026-05-14

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biolog…

loading…
Indicators:|

Key Statistics

Valuation
P/E (Trailing)
P/E (Forward)-33.08
PEG1.43
P/B1.01
P/S1.10
EV/EBITDA-45.70
EV/Revenue1.02
EPS (TTM)-1.09
EPS (Forward)-0.14
Cash Flow & Leverage
FCF Yield12.02%
FCF Margin13.23%
Operating CF-9.18M EUR
CapEx (TTM)82.62M EUR
Net Debt/EBITDA3.43
Net Debt-57.30M EUR
Technical
SMA 504.847 (-3.0%)
SMA 2005.721 (-17.9%)
Beta1.30
S&P 52W Chg24.23%
Avg Vol (30d)976.68K
Avg Vol (10d)1.04M
Technical Indicators
RSI (14)40.6
MACD-0.0285
MACD Signal0.0611
MACD Hist.-0.0896
BB Upper5.869 EUR
BB Middle5.283 EUR
BB Lower4.696 EUR
BB Width22.21%
ATR (14)0.3477 EUR
Vol Ratio (20d)0.62x
52W Range
3.99515% of range8.566
52W High8.566 EUR
52W Low3.995 EUR
Profitability
Gross Margin14.49%
EBITDA Margin-2.24%
Profit Margin-13.13%
Oper. Margin-29.64%
ROE-12.72%
ROA-6.04%
Revenue Growth-21.70%
Earnings Growth
Balance Sheet
Debt/Equity0.55
Current Ratio1.68
Quick Ratio1.45
Book Value/Sh4.578 EUR
Cash/Share2.505 EUR
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 EUR
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Splits
Last Split2:1
Split DateAug 18, 2000
Ownership
Shares Out.177.59M
Float133.41M
Insiders9.97%
Institutions63.49%
Analyst Consensus
Rating1.9 (Buy)
Target (Mean)6.443 EUR
Target Range4.000 EUR10.00 EUR
# Analysts7
Company
Market Cap820.13M EUR
Enterprise Value762.68M EUR
Revenue (TTM)745.04M EUR
Gross Profit114.22M EUR
Net Income (TTM)-103.52M EUR
Revenue/Share4.195 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees4.5K
Last Price4.700 EUR
CountryDE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN